Oncotherapy’s Pancreatic Cancer Candidate Fails Phase III Trial
This article was originally published in PharmAsia News
Executive Summary
Kawasaki-based Oncotherapy Science Inc. announced Feb. 28 the result of a Phase III trial for cancer treatment Elpamotide (OTS102) in patients with pancreatic cancer.